drugset / Trial / NCT05722925
Evaluating Fluciclovine PET in Patients With Biochemical Recurrence of Prostate Cancer and a Negative PSMA PET
Phase 4
Active not recruiting
50 enrolled
OHSU Knight Cancer Institute
Blue Earth Diagnostics · collabOregon Health and Science University · collab
NaSingle-groupOpen-labelDiagnostic
Summary
The purpose of this prospective cohort study is to investigate the role of Fluciclovine Positron Emission Tomography (PET) in patients with biochemical recurrence of prostate cancer (BCR) and a negative Prostate Specific Membrane Antigen (PSMA) PET, specifically, whether Fluciclovine PET can help detect local recurrence and whether the results of Fluciclovine PET can change management.
Timeline
- Start
- 2023-10-04
- Primary completion
- 2026-12-01
- Completion
- 2026-12-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Fluciclovine | Diagnostic / imaging agent | 296 mbq | Intravenous |